全文获取类型
收费全文 | 56662篇 |
免费 | 6711篇 |
国内免费 | 1384篇 |
专业分类
耳鼻咽喉 | 286篇 |
儿科学 | 1454篇 |
妇产科学 | 1186篇 |
基础医学 | 4407篇 |
口腔科学 | 1536篇 |
临床医学 | 6508篇 |
内科学 | 11102篇 |
皮肤病学 | 551篇 |
神经病学 | 4706篇 |
特种医学 | 1364篇 |
外国民族医学 | 1篇 |
外科学 | 5385篇 |
综合类 | 5706篇 |
现状与发展 | 10篇 |
一般理论 | 10篇 |
预防医学 | 9983篇 |
眼科学 | 929篇 |
药学 | 4737篇 |
30篇 | |
中国医学 | 611篇 |
肿瘤学 | 4255篇 |
出版年
2024年 | 198篇 |
2023年 | 1354篇 |
2022年 | 2205篇 |
2021年 | 3211篇 |
2020年 | 3020篇 |
2019年 | 2838篇 |
2018年 | 2809篇 |
2017年 | 2675篇 |
2016年 | 2698篇 |
2015年 | 2515篇 |
2014年 | 4077篇 |
2013年 | 5274篇 |
2012年 | 3058篇 |
2011年 | 3406篇 |
2010年 | 2609篇 |
2009年 | 2580篇 |
2008年 | 2650篇 |
2007年 | 2372篇 |
2006年 | 2149篇 |
2005年 | 1892篇 |
2004年 | 1545篇 |
2003年 | 1340篇 |
2002年 | 1158篇 |
2001年 | 1045篇 |
2000年 | 770篇 |
1999年 | 644篇 |
1998年 | 590篇 |
1997年 | 518篇 |
1996年 | 372篇 |
1995年 | 386篇 |
1994年 | 318篇 |
1993年 | 337篇 |
1992年 | 275篇 |
1991年 | 248篇 |
1990年 | 220篇 |
1989年 | 214篇 |
1988年 | 174篇 |
1987年 | 155篇 |
1986年 | 144篇 |
1985年 | 154篇 |
1984年 | 132篇 |
1983年 | 79篇 |
1982年 | 84篇 |
1981年 | 77篇 |
1980年 | 59篇 |
1979年 | 35篇 |
1978年 | 25篇 |
1977年 | 26篇 |
1976年 | 14篇 |
1974年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
3.
《American journal of surgery》2023,225(1):198-205
BackgroundLiver resection is commonly performed for hepatic tumors, however preoperative risk stratification remains challenging. We evaluated the performance of contemporary prediction models for short-term mortality after liver resection in patients with and without cirrhosis.MethodsThis retrospective cohort study examined National Surgical Quality Improvement Program data. We included patients who underwent liver resections from 2014 to 2019. VOCAL-Penn, MELD, MELD-Na, ALBI, and Mayo risk scores were evaluated in terms of model discrimination and calibration for 30-day post-operative mortality.ResultsA total 15,198 patients underwent liver resection, of whom 249 (1.6%) experienced 30-day post-operative mortality. The VOCAL-Penn score had the highest discrimination (area under the ROC curve [AUC] 0.74) compared to all other models. The VOCAL-Penn score similarly outperformed other models in patients with (AUC 0.70) and without (AUC 0.74) cirrhosis.ConclusionThe VOCAL-Penn score demonstrated superior predictive performance for 30-day post-operative mortality after liver resection as compared to existing clinical standards. 相似文献
4.
5.
《Diagnostic Histopathology》2022,28(11):493-500
After decades of relative stagnation lung cancer is emerging as a disease type where rapid progress is being made in diagnosis and therapy, as well as in our understanding of disease biology. Much of this progress is of immediate impact to diagnosticians, and more is likely to affect diagnostic practice in the near future. In this review we seek to briefly summarize several key areas of active research of immediate or probable imminent value to trainee and consultant pulmonary pathologists alike. We cover some major changes in tumour classification, grading, and patient stratification, as well as considering the state of the art in machine-assisted interpretation of lung cancer histology, and the use of genetically modified lung cancer models. 相似文献
6.
7.
8.
9.
10.